Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders.
This review focuses on possible causes and the impact of different immune states in schizophrenia and major depression. It discusses the fact that, in schizophrenia, an over-activation of the type 2 immune response may dominate, while the type 1 and the pro-inflammatory immune responses are over-activated in major depression. The consequence of these diverse immune states is the activation and, respectively, inhibition of different enzymes in tryptophan/kynurenine metabolism, which may lead to an overemphasis of N-methyl-D-aspartate (NMDA) receptor antagonism in schizophrenia and of NMDA-receptor agonism in depression, resulting in glutamatergic hypofunction in schizophrenia and glutamatergic hyperfunction in major depression. In addition, the activation of the type 1 and the pro-inflammatory immune responses in major depression result in increased serotonin degradation and a serotonergic deficit. While antipsychotics and antidepressants today mainly act on the dopaminergic-glutamatergic and the noradrenergic-serotonergic neurotransmission, anti-inflammatory and immune-modulating therapies might act more basically at the pathophysiological mechanism. The limitations of this concept, however, are critically discussed.
Müller
Norbert
N
Ludwig-Maximilians-Universität München, Hospital for Psychiatry and Psychotherapy, 80336 München, Germany. Norbert.Mueller@med.uni-muenchen.de
Schwarz
Markus J
MJ
D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000276:immunology; D001921:Brain / Q000187:drug effects / Q000276:immunology*; D004703:Endocrine System / Q000276:immunology*; D006801:Humans; D018448:Models, Immunological; D008959:Models, Neurological; D019964:Mood Disorders / Q000188:drug therapy / Q000276:immunology*; D015213:Neuroimmunomodulation / Q000276:immunology*; D012559:Schizophrenia / Q000188:drug therapy / Q000276:immunology*; D009435:Synaptic Transmission / Q000276:immunology
D014150:Antipsychotic Agents